This article is more than 5 years old. Information may no longer be current.
More than 300 clinicians contributed data to RISE
Click Here to Manage Email Alerts
Across 55 sites, 312 clinicians have contributed data to the Rheumatology Informatics System for Effectiveness national registry since its launch by the American College of Rheumatology in 2014, according to a recently published study.
“The enthusiastic participation of U.S. rheumatologists has allowed the registry to grow quickly since its launch in 2014,” Jinoos Yazdany, MD, MPH, associate professor in the Division of Rheumatology at the University of California in San Francisco, and colleagues wrote. “[Rheumatology Informatics System for Effectiveness] RISE represents the first attempt to create a national EHR-enabled rheumatology registry in the [United States] U.S., thereby avoiding separate entry of data by clinicians or office staff.”
RISE — certified as a CMS-qualified clinical data Registry — extracts electronic health record data from each clinical practice, analyzes the data at a central location and then feeds this analysis back to clinicians in the form of a web-based tool, the researchers wrote. RISE allows rheumatologists to track quality-of-care performance and efficiency at a national scale without individual patient informed consent.
In this study, Yazdany and colleagues analyzed RISE data from 2014 to 2015. They assessed medication use and performance among patients with rheumatoid arthritis (RA). Across 55 sites, data from 239,302 patients were contributed by 321 clinicians. Of these clinicians, 72% were in group practice; 21% were in solo practice; and 7% were part of a larger health system. Among patients with RA, 34.4% were taking a biologic or synthetic disease-modifying antirheumatic drug (DMARD) at last encounter and 66.7% were taking a nonbiologic DMARD. In the last year, 91% of patients were taking a DMARD. Overall, 55.2% of patients had their disease activity score recorded and 53.6% had their functional status score recorded.
“We are encouraged by the fact that over one-half of rheumatologists participating in RISE are routinely capturing this information in practice,” the researchers wrote. “Measurement of these outcomes using validated tools enables evidence-based care by facilitating a treat-to-target approach in RA, and also allows for tracking of outcomes and benchmarking across rheumatology practices.” – by Will Offit
Disclosure: Yazdany reports receipt of an independent research award from Pfizer.
Click Here to Manage Email Alerts